Outlining the key touchpoints for embracing change and opportunity in the “messy, tough—and fun” R&D-to-commercial transition journey.
Carlos Martin
Advertisement
Strategic Advisor, Rocket Pharmaceuticals
Articles by Carlos Martin
Advertisement
Latest Updated Articles
From Lab to Market: Tracking Today’s Shifting Pathways for BiotechSeptember 17th 2025
Advertisement
Advertisement
Trending on PharmExec
1
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
2
Pharming CEO Fabrice Chouraqui Steps Down Amid Strategic Disagreement with Board
3
Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboartion with Summit Therapeutics
4
As Peptide Rulemaking Stalls, FDA Enforcement Moves Forward
5